IP Library Granted Patent US 10,179,148
Granted Patent B2
US 10,179,148 · App. 14/571,054 · Granted Jan 15, 2019

Keratolytic composition with anti-allergic anti-inflammatory properties

Inventor: Medasani Munisekhar (Hyderabad, IN)
A61K33/02A61K8/20A61K8/416A61K8/463A61K8/97A61K31/11A61K31/205A61K33/14A61K36/898A61Q5/00A61Q5/006A61Q5/02A61Q19/00A61Q19/007A61Q19/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,148
App. No.
14/571,054
Granted
Jan 15, 2019
Kind
B2
Abstract

A product with an enhanced medicinal and cosmetic composition with a specific utility of “Psoriasis, Eczema and like skin disorders application” is characterized by the fact that it comprises active agents and ingredients as vanilla extract, ammonium chloride, potassium chloride and quaternary ammonium compound having formulated at a specific pH value with other specially selected adjuvants and fillers.

Claims (12)

1. A method of treating a skin disorder, the method comprising:

administering to an area of skin exhibiting the skin disorder a composition comprising:

active components that treat the skin disorder, the active components that treat the skin disorder consist of:

at least one of vanilla extract, vanilla oil and vanillin in an amount of from about 0.1% to less than 2% by weight of the composition;

quaternary ammonium in an amount from about 0.001% to about 40% by weight of the composition; and

a cation chloride salt in an amount from about 0.001% to about 10% by weight of the composition, the cation chloride salt being selected from the group consisting of ammonium chloride and potassium chloride,

wherein

the skin disorder is selected from the group consisting of psoriasis, eczema, dermatitis, acne, and dandruff, and

the pH of the composition is greater than about 3.0 and less than about 7.0.

2. The method of claim 1 , comprising topically administering the composition on a daily basis for at least 4 days, to an area of skin exhibiting the disorder.

3. The method of claim 1 , wherein the composition is topically administered in the form of a lotion, cream, ointment, emulsion solution, patch, pad, cleanser, conditioner, gel, soap, sprays, foam, or tape.

4. The method of claim 1 , wherein the composition is a pharmaceutical or cosmetic preparation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2024
From: MEDASANI, MUNISEKHAR
To: ASTREL GENOME LIMITED
Reel/Frame 069477/0315 →
Priority Claims (1)
IN 185/KOL/2003 · Mar 27, 2003 · national
Continuity (2)
Continuation 10551001
Related Publication 20150164941A1 · Jun 18, 2015